HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cocrystal Pharma (NASDAQ:COCP) and maintained its $10 price target on the stock.

April 04, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Cocrystal Pharma with a $10 price target.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence among investors and could lead to a positive short-term impact on COCP's stock price. Analyst ratings and price targets are significant indicators for investors, and a positive outlook from a well-regarded firm can contribute to bullish sentiment around the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100